Log in

Xenon Pharmaceuticals Stock Forecast, Price & News

-0.24 (-2.10 %)
(As of 09/21/2020 12:00 AM ET)
Today's Range
Now: $11.20
50-Day Range
MA: $11.41
52-Week Range
Now: $11.20
Volume112,189 shs
Average Volume219,510 shs
Market Capitalization$391.94 million
P/E RatioN/A
Dividend YieldN/A
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Read More
Xenon Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XENE



Sales & Book Value

Annual Sales$6.83 million
Book Value$2.99 per share


Net Income$-41,600,000.00
Net Margins-102.25%


Market Cap$391.94 million
Next Earnings Date11/3/2020 (Estimated)
-0.24 (-2.10 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

How has Xenon Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XENE stock has decreased by 11.9% and is now trading at $11.20.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xenon Pharmaceuticals

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Xenon Pharmaceuticals

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings results on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to the consensus estimate of $7.50 million. Xenon Pharmaceuticals had a negative return on equity of 21.76% and a negative net margin of 102.25%.
View Xenon Pharmaceuticals' earnings history

What price target have analysts set for XENE?

5 brokerages have issued 12-month price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $22.00 to $25.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $23.25 in the next twelve months. This suggests a possible upside of 107.6% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,390,000 shares, an increase of 14.9% from the August 15th total of 1,210,000 shares. Based on an average trading volume of 140,000 shares, the days-to-cover ratio is currently 9.9 days.
View Xenon Pharmaceuticals' Short Interest

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (10.05%), Orbimed Advisors LLC (7.14%), FMR LLC (6.28%), FMR LLC (6.28%), Bank of New York Mellon Corp (2.27%) and Point72 Asset Management L.P. (1.88%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Knott David M.
View insider buying and selling activity for Xenon Pharmaceuticals

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Orbimed Advisors LLC, FMR LLC, FMR LLC, Bank of New York Mellon Corp, Marshall Wace LLP, Point72 Asset Management L.P., and Swiss National Bank.
View insider buying and selling activity for Xenon Pharmaceuticals

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $11.20.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $391.94 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.